

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



115

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A01N 43/04, A61K 31/70		A1	(11) International Publication Number: WO 94/18835
			(43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/US94/01748		(81) Designated States: AU, CA, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 February 1994 (18.02.94)			
(30) Priority Data: 08/019,543 19 February 1993 (19.02.93) US		Published With international search report.	
(71) Applicant: GENTA INCORPORATED [US/US]; 3550 General Atomics Court, San Diego, CA 92121 (US).			
(72) Inventors: HARPER, Mary, Ellen; 2433 Unicornio Street, Carlsbad, CA 92009 (US). WOOLF, Tod, Mitchell; Apartment G, 519 Stratford Court, Del Mar, CA 92014 (US). ARNOLD, Lyle, John, Jr.; 15638 Boulder Mountain Road, Poway, CA 92064 (US).			
(74) Agents: BIGGS, Suzanne, L. et al.; Lyon & Lyon, 34th floor, 611 West Sixth Street, Los Angeles, CA 90017 (US).			
(54) Title: TREATMENT OF ANDROGEN-ASSOCIATED BALDNESS USING ANTISENSE OLIGOMERS			
(57) Abstract Methods of treating androgen-associated hair loss, in particular decreasing the progression of male pattern baldness using nucleoside Oligomers and Oligomers useful in the described methods are provided.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONTreatment of Androgen-Associated
Baldness Using Antisense OligomersCross-Reference to Related Applications

The present application is a continuation in part of United States Serial No. 07/707,897 filed May 31, 1991, the disclosure of which is incorporated herein by
5 references.

Background and Introduction to the Invention

Androgens are steroid hormones found circulating at varying levels in both men and women. They are essential in sex differentiation, development, and reproductive
10 function. However, androgens can also play a role in undesirable physiological conditions, including different types of baldness.

One of the most prevalent types of baldness is male pattern baldness (MPB). This condition is widespread, affecting two of every three men. MPB, which is inherited as a autosomal dominant trait with partial penetrance, is known to be androgen-dependent. This is evidenced in the fact that castrated males do not develop baldness.
15

Hair follicles initially appear in utero. No new
20 follicles are created after birth, and it is believed that none are lost in adult life. However, in MPB, hair follicles do become progressively smaller (miniaturized). Hair follicles exhibit cyclic activity. Each period of active growth of hair (anagen) alternates with a resting period (telogen), separated by a relatively short transition phase (catagen). Hair growth on the human scalp is a mosaic of follicular activity with each follicle at a stage independent of its neighbors. At any one time, between 4-24% (average 13%) of follicles are in telogen
25 and <1% in catagen. Hairs reach a terminal or definitive length, which depends mainly on the duration of anagen,
30

SUBSTITUTE SHEET (RULE 26)

and partly on the rate of growth. In the human scalp, anagen may occupy three years or more; however, the percentage of follicles in telogen increases with age, resulting in a gradual thinning. In MPB, the ratio of
5 telogen to anagen is increased still further. Also, in MPB the hairs in affected areas become steadily shorter and finer, and ultimately may be reduced to the short (<2cm), fine, unpigmented hair known as vellus hair.

Although the endocrine system does not directly
10 initiate or curtail the activity of the hair follicle, androgens do accelerate or retard the normal cyclic activity of hair growth described above.

Testosterone (T) is the major circulating androgen. Because circulating T is largely bound to sex hormone
15 binding globulin (SHBG), the availability of T depends not only on its total concentration, but also on the level of SHBG. While plasma T levels in MPB appear to be normal, SHBG levels tend to be low. This implies that bald males may have higher levels of free testosterone. This
20 implication is borne out by the demonstration that bald males have high T concentrations in their saliva.

T itself has minimal activity in the hair follicle. A much more active metabolite which is believed to be responsible for MPB is 5-alpha-dihydrotestosterone (DHT).
25 DHT is formed in the cytoplasm of hair follicle cells after reduction of T by the enzyme 5-alpha-reductase. Because balding men have increased 5-alpha-reductase activity in the hair follicles and skin of the frontal scalp, it has been suggested that this enzyme may be
30 involved in development of MPB. Two genes have been reported, each of which codes for a distinct 5-alpha-reductase enzyme (Genbank locus:HUM5AR and HUMSRDA).

The effects of androgens in MPB are mediated by the binding of an androgen (primarily DHT) to the androgen
35 receptor (AR). Androgens bind specifically to the AR, which is either situated in the nucleus or transferred to it from the cytoplasm. The AR belongs to a subfamily of

steroid/thyroid hormone/retinoic acid receptors, whose activity is controlled by the tight and specific binding of the cognate ligand. Evidence for the involvement of the AR in MPB includes the demonstration that androgenic alopecia (a type of pattern baldness in women) can be alleviated by treatment with antiandrogens. These antiandrogens, such as spironolactone, cyproterone acetate, flutamide and cimetidine, bind to the AR and competitively inhibit DHT binding. In addition, sebaceous glands of bald scalps were found to have greater binding affinity and capacity for androgens than those in hairy scalps.

In the past, baldness was treated only with surgical procedures, such as hair transplants and scalp reduction. Recently, however, there have been some advances in medical treatment of baldness. The most publicized of these is minoxidil (Rogaine[™]). Minoxidil is a potent vasodilator which has been used as a treatment for hypertension. A noted side effect of this treatment was the growth of hair on parts of the body. This led to the testing of topical minoxidil on balding areas of the scalp. The result in some cases was an apparent decrease in vellus hairs with a concomitant increase in terminal hairs. Many of the subjects studied reported that their rate of hair loss decreased. However, not all subjects responded to treatment with minoxidil. It was found that younger men who only recently (within five years) had begun to bald responded better than older men, and that minoxidil worked best on small areas of vertex baldness.

Research indicates that minoxidil will not help the majority of balding men, although it does help a specific population of minimally balding young men. The reason for the effectiveness of minoxidil is not known. It might be due to an increase in blood flow caused by the vasodilating effect of the drug. The longterm effects of minoxidil treatment are not known.

Other treatments are directed at reducing the production of DHT from testosterone, thereby preventing its cytosol-nuclear binding and/or translocation. Topical or intralesional progesterone can also be used to reduce the production of DHT from T. Since progesterone is similar in structure to testosterone, it competes with testosterone for 5-alpha-reductase, the enzyme that converts testosterone to DHT.

Summary of the Invention

The present invention is directed to methods of treating androgen-associated hair loss, particularly hair loss in men, more particularly to methods of decreasing the progression of male pattern baldness and also to pharmaceutical compositions useful for these methods. These methods and pharmaceutical compositions are particularly suited to the treatment of hair loss associated with increased levels of protein-bound DHT in scalp. According to one aspect, Oligomers complementary to a target sequence in genes which result in increased amounts of androgen receptor bound-5- α -dihydrotestosterone in scalp tissue are used to down-regulate genes or their transcription products.

The topography of male pattern baldness has to do with both the number of androgen receptor ("AR") molecules of the follicular cells and the activity of 5-alpha-reductase ("5- α -RE") in different areas of the scalp. Thus, targeting 5-alpha reductase or the AR would be useful in developing a treatment for MPB. However, it is essential that the treatment act only at the scalp and is cleared quickly from the body, since systemic inhibition of testosterone or DHT activity would be highly disadvantageous in men, resulting in undesirable feminization.

The androgen receptor may be involved in other types of hair loss aside from MPB. For example, androgenic alopecia, a type of hair loss in women, has been shown to respond to treatment with antiandrogens. Accordingly, the

SUBSTITUTE SHEET (RULE 26)

methods and pharmaceutical compositions of the present invention may be useful in the treatment of other types of androgen-associated hair loss. Also, these methods and compositions may be useful in treating other conditions
5 where localized (as opposed to systemic) down-regulation of the AR or 5- α -RE is desirable. Accordingly, the present invention is also directed to methods of decreasing levels of protein-bound 5-alpha-dihydro-testosterone in a localized and tissue-specific manner
10 without significantly interfering with testosterone metabolism in other tissues or systemically by exposing the cells of the tissue to be treated with an Oligomer or Oligomers which inhibit or alter expression of the AR or 5- α -RE. Such Oligomers include those which interact with
15 a target sequence selected from a gene coding for the AR or 5- α -RE or a sequence immediately upstream from the transcription site of the gene or their transcription products.

Thus, in one aspect, the present invention is
20 directed to a method of treating androgen-associated hair loss by decreasing levels of 5-alpha-dihydrotestosterone which are present in follicles and bound to protein, and according to a preferred aspect decreasing levels of DHT bound to the androgen receptor in scalp tissue without
25 significantly interfering with testosterone synthesis and/or metabolism in other tissues. This method comprises exposing scalp cells to an amount of an Oligomer or Oligomers sufficient to provide a decrease in the rate of hair loss, preferably by a cosmetically significant
30 amount. The Oligomer or Oligomers interact with a gene coding for the AR or 5- α -RE or a sequence immediately upstream from the transcription start site of the gene or their transcription products and thereby inhibit or alter expression of the AR or 5- α -RE.

35 Suitable Oligomers for use in the methods and pharmaceutical compositions of the present invention include (a) an antisense Oligomer having a sequence complementary to

SUBSTITUTE SHEET (RULE 26)

a sequence of RNA transcribed from a target gene present in the cells; (b) an antisense Oligomer having a nucleoside sequence complementary to a single stranded DNA target sequence; (c) an antisense Oligomer having a
5 nucleoside sequence complementary to a single RNA or DNA strand contained within a duplex (d) a Third Strand Oligomer having a sequence complementary to a selected double stranded nucleic acid sequence of a target gene present in the cells; and (e) a Triplex Oligomer Pair
10 which is complementary to a single-stranded nucleic acid sequence of a target gene or its transcription product or to a single-stranded sequence contained within a duplex. The target gene is advantageously selected from the group consisting of those genes encoding 5-alpha-reductase and
15 the androgen receptor. According to a preferred aspect, the Oligomer is applied topically to the scalp tissue.

According to an alternate aspect, the present invention is directed to a method of treating androgen-associated hair loss which comprises exposing scalp to an
20 amount of an Oligomer which decreases the rate of hair loss wherein said Oligomer is selected from an antisense Oligomer having a sequence complementary to that of RNA transcribed from a gene for androgen receptor or an antisense Oligomer having a sequence complementary to a
25 sequence of RNA transcribed from a gene for 5-alpha-reductase.

According to a preferred aspect the Oligomer is a neutral Oligomer. Neutral Oligomers such as methylphosphonate Oligomers are cleared rapidly through the kidneys.
30 Especially preferred are methylphosphonate Oligomers, which are rapidly cleared from the plasma and are excreted in the urine.

The Oligomers used according to the present invention preferably comprise Oligomers which have a neutral backbone.
35 Neutral Oligomers are preferred, in part, due to their advantageous uptake through the skin when applied topically. Preferably these Oligomers are substantially

SUBSTITUTE SHEET (RULE 26)

neutral. More preferably, neutral Oligomers are used. Particularly preferred are substantially neutral methylphosphonate Oligomers. According to an especially preferred aspect, neutral methylphosphonate Oligomers are
5 employed.


Definitions

As used herein, the following terms have the following meanings unless expressly stated to the contrary.

The term "purine" or "purine base" includes not only
10 the naturally occurring adenine and guanine bases, but also modifications of those bases such as bases substituted at the 8-position, or guanine analogs modified at the 6-position or the analog of adenine, 2-amino purine, as well as analogs of purines having carbon replacing
15 nitrogen at the 9-position such as the 9-deaza purine derivatives and other purine analogs.


The term "nucleoside" includes a nucleosidyl unit and is used interchangeably therewith, and refers to a subunit of a nucleic acid which comprises a 5-carbon sugar and a
20 nitrogen-containing base. The term includes not only those nucleosidyl units having A, G, C, T and U as their bases, but also analogs and modified forms of the naturally-occurring bases, including the pyrimidine-5-donor/acceptor bases such as pseudoisocytosine and
25 pseudouracil and other modified bases (such as 8-substituted purines). In RNA, the 5-carbon sugar is ribose; in DNA, it is 2'-deoxyribose. The term nucleoside also includes other analogs of such subunits, including those which have modified sugars such as 2'-O-alkyl
30 ribose.

5 The term "phosphonate" refers to the group $\text{O}=\text{P}-\text{R}$



wherein R is hydrogen or an alkyl or aryl group. Suitable
alkyl or aryl groups include those which do not sterically
10 hinder the phosphonate linkage or interact with each
other. The phosphonate group may exist in either an "R"
or an "S" configuration. Phosphonate groups may be used
as internucleosidyl phosphorus group linkages (or links)
to connect nucleosidyl units.

15 The term "phosphodiester" or "diester" refers to



wherein phosphodiester groups may be used as inter-
nucleosidyl phosphorus group linkages (or links) to
25 connect nucleosidyl units.

A "non-nucleoside monomeric unit" refers to a mono-
meric unit wherein the base, the sugar and/or the phos-
phorus backbone has been replaced by other chemical
moieties.

30 A "nucleoside/non-nucleoside polymer" refers to a
polymer comprised of nucleoside and non-nucleoside
monomeric units.

The term "oligonucleoside" or "Oligomer" refers to a
chain of nucleosides which are linked by internucleoside
35 linkages which is generally from about 4 to about 100
nucleosides in length, but which may be greater than about
100 nucleosides in length. They are usually synthesized
from nucleoside monomers, but may also be obtained by
enzymatic means. Thus, the term "Oligomer" refers to a
40 chain of oligonucleosides which have internucleosidyl
linkages linking the nucleoside monomers and, thus,

includes oligonucleotides, nonionic oligonucleoside alkyl- and aryl-phosphonate analogs, alkyl- and aryl-phosphonothioates, phosphorothioate or phosphorodithioate analogs of oligonucleotides, phosphoramidate analogs of oligonucleotides, neutral phosphate ester oligonucleoside analogs, such as phosphotriesters and other oligonucleoside analogs and modified oligonucleosides, and also includes nucleoside/non-nucleoside polymers. The term also includes nucleoside/non-nucleoside polymers wherein one or more of the phosphorus group linkages between monomeric units has been replaced by a non-phosphorous linkage such as a formacetal linkage, a thioformacetal linkage, a sulfamate linkage, or a carbamate linkage. It also includes nucleoside/non-nucleoside polymers wherein both the sugar and the phosphorous moiety have been replaced or modified such as morpholino base analogs, or polyamide base analogs. It also includes nucleoside/non-nucleoside polymers wherein the base, the sugar, and the phosphate backbone of a nucleoside are either replaced by a non-nucleoside moiety or wherein a non-nucleoside moiety is inserted into the nucleoside/non-nucleoside polymer. Optionally, said non-nucleoside moiety may serve to link other small molecules which may interact with target sequences or alter uptake into target cells.

The term "alkyl- or aryl-phosphonate Oligomer" refers to Oligomers having at least one alkyl- or aryl-phosphonate internucleosidyl linkage. Suitable alkyl- or aryl- phosphonate groups include alkyl- or aryl- groups which do not sterically hinder the phosphonate linkage or interact with each other. Preferred alkyl groups include lower alkyl groups having from about 1 to about 6 carbon atoms. Suitable aryl groups have at least one ring having a conjugated pi electron system and include carbocyclic aryl and heterocyclic aryl groups, which may be optionally substituted and preferably having up to about 10 carbon atoms.

SUBSTITUTE SHEET (RULE 26)

The term "methylphosphonate Oligomer" (or "MP-Oligomer") refers to Oligomers having at least one methylphosphonate internucleosidyl linkage.

The term "neutral Oligomer" refers to Oligomers which
5 have nonionic internucleosidyl linkages between nucleoside monomers (i.e., linkages having no positive or negative ionic charge) and include, for example, Oligomers having internucleosidyl linkages such as alkyl- or aryl- phosphonate linkages, alkyl- or aryl-phosphonothioates,
10 neutral phosphate ester linkages such as phosphotriester linkages, especially neutral ethyltriester linkages; and non-phosphorus-containing internucleosidyl linkages, such as sulfamate, morpholino, formacetal, thioformacetal, and carbamate linkages. Optionally, a neutral Oligomer may
15 comprise a conjugate between an oligonucleoside or nucleoside/non-nucleoside polymer and a second molecule which comprises a conjugation partner. Such conjugation partners may comprise intercalators, alkylating agents, binding substances for cell surface receptors, lipophilic
20 agents, nucleic acid modifying groups including photo-cross-linking agents such as psoralen and groups capable of cleaving a targeted portion of a nucleic acid, and the like. Such conjugation partners may further enhance the uptake of the Oligomer, modify the interaction of the
25 Oligomer with the target sequence, or alter the pharmacokinetic distribution of the Oligomer. The essential requirement is that the oligonucleoside or nucleoside/non-nucleoside polymer that the Oligomer conjugate comprises be substantially neutral and capable of hybridizing to its
30 complementary target sequence.

The term "substantially neutral" in referring to an Oligomer refers to those Oligomers in which at least about 80 percent of the internucleosidyl linkages between the nucleoside monomers are nonionic linkages.

35 The term "neutral alkyl- or aryl- phosphonate Oligomer" refers to neutral Oligomers having neutral

SUBSTITUTE SHEET (RULE 26)

internucleosidyl linkages which comprise at least one alkyl- or aryl- phosphonate linkage.

The term "neutral methylphosphonate Oligomer" refers to neutral Oligomers having internucleosidyl linkages
5 which comprise at least one methylphosphonate linkage.

The term "tandem oligonucleotide" or "tandem Oligomer" refers to an oligonucleotide or Oligomer which is complementary to a sequence located either on the 5'- or 3'- side of a target nucleic acid sequence and which is
10 co-hybridized with a second Oligomer which is complementary to the target sequence. Tandem Oligomers may improve hybridization of these Oligomers to the target by helping to make the target sequence more accessible to such Oligomers, such as by decreasing the secondary
15 structure of the target nucleic acid sequence. In addition, one member of a pair of tandem Oligomers may improve the hybrid stability of the second tandem Oligomer to the target nucleic acid sequence by promoting a helical structure at either the 5'- or 3'-end of said second
20 Oligomer and vice-versa.

The term "short chain aliphatic alcohol" refers to an alcohol having from about 2 to about 20 carbon atoms in which the aliphatic (alkyl) chain may be either straight chained or branch chained and includes primary, secondary
25 and tertiary alcohols, glycols and polyols.

The term "flux enhancer" refers to a substance which is used to increase transdermal flux of a compound. A flux enhancer is typically applied to skin or mucous membrane in combination with the compound to increase
30 transdermal flux of the compound. Enhancers are believed to function by disrupting the skin or mucous membrane barrier or by changing the partitioning behavior of the drug in the skin or mucous membrane.

The term "Triplex Oligomer Pair" refers to first and
35 second Oligomers which are optionally covalently linked at one or more sites and which are complementary to and are capable of hydrogen bonding to a segment of a single

SUBSTITUTE SHEET (RULE 26)

stranded target nucleic acid, such as RNA or DNA, and, thus, together with the single stranded target nucleic acid, are capable of forming a triple helix structure therewith.

5 The term "Third Strand Oligomer" refers to Oligomers which are capable of hybridizing to a segment of a double stranded nucleic acid, such as a DNA duplex, an RNA duplex or a DNA-RNA duplex, and forming a triple helix structure therewith.

10 The term "complementary," when referring to a Triplex Oligomer Pair (or first and second Oligomers) or to a Third Strand Oligomer, refers to Oligomers having base sequences which are capable of forming or recognizing hydrogen bonds (and base pairing or hybridizing) with the
15 base sequence of the nucleic acid to form a triple helix structure.

 The term "substantially complementary" refers to Oligomers, including Triplex Oligomer Pairs or Third Strand Oligomers which may lack a complement for each
20 nucleoside in the target sequence, have sufficient binding affinity for the target sequence to form a stable duplex or triple helix complex, as the case may be, and thereby specifically recognize the target sequence and selectively inhibit or down-regulate its expression.

25 The term "triplet" or "triad" refers to a hydrogen bonded complex of the bases of three nucleosides between a base (if single stranded) or bases (if double stranded) of a target sequence, a base of a Second Strand and a Third Strand (if a single stranded target sequence) or a
30 base of a Third Strand (if a double-stranded target).

Brief Description of the Drawings

Figure 1 depicts thermal denaturation profiles for double stranded and triple-stranded complexes formed between Oligomer 2 and a target sequence.

35 Figure 2 depicts clearance from plasma of a tritium-labelled tetramer in a mouse model.

Figure 3 depicts clearance from plasma of a tritium labelled dodecamer in a mouse model.

Detailed Description of the Invention

According to the present invention, methods of
5 arresting and/or diminishing the progression of conditions
characterized by androgen-associated hair loss, particularly scalp hair loss in men, and more particularly that
condition known as male pattern baldness are provided. These methods diminish and/or arrest the progression of
10 hair loss by decreasing amounts of 5-alpha-dihydro-
testosterone-androgen receptor complex present in scalp
tissue. This decrease may be obtained by either down-
regulation of synthesis of androgen receptor or of 5-
alpha-dehydrotestosterone ("DHT"). Synthesis of DHT may
15 be down-regulated by decreasing levels of 5-alpha
reductase present in scalp tissue. Such down-regulation
may be effected by use of an Oligomer which may bind to a
protein's active site to modulate its function or
Oligomers such as antisense Oligomers, Third Strand
20 Oligomers and Triplex Oligomer pairs. Suitable nucleoside
sequences for these Oligomers may be determined from the
sequences of target genes. Preferred sequences of the
target region are described herein.

A. Preferred Oligomers

25 The Oligomer selected may be any of a number of
types, including those having a charged or uncharged
backbone.

Preferred Oligomers include alkyl- and aryl-
phosphonate Oligomers, especially preferred are
30 methylphosphonate Oligomers. Other preferred Oligomers
include phosphorothioate Oligomers, morpholino analogs,
formacetal analogs and peptide nucleic acid ("PNA")
analogues.

Preferably the Oligomers each comprise from about 4
35 to about 40 nucleosides, more preferably, from about 6 to

30 nucleosides. Especially preferred are Oligomers of about 8 to about 20 nucleosides.

According to an alternately preferred aspect, tandem Oligomers are employed. Preferred tandem Oligomers include those which comprise a total of about 20 to about 40 nucleosides.

Oligomers having the selected internucleoside linkages may be conveniently prepared according to synthetic techniques known to those skilled in the art. For example, commercial machines, reagents and protocols are available for the synthesis of Oligomers having phosphodiester and certain other phosphorus-containing internucleoside linkages. See also Gait, M.J., Oligonucleotide Synthesis: A Practical Approach (IRL Press, 1984); Cohen, Jack S., Oligodeoxynucleotides Antisense Inhibitors of Gene Expression, (CRC Press, Boca Raton, FL, 1989); and Oligonucleotides and Analogues: A Practical Approach, (F. Eckstein, 1991). Preparation of Oligomers having certain non-phosphorus-containing internucleoside linkages is described in United States Patent No. 5,142,047, the disclosure of which is incorporated herein by reference.

According to an alternately preferred aspect, chirally pure Oligomers are used according to the present invention. Alternatively, Oligomers comprising at least one chirally pure internucleosidyl linkage may be used and may be preferred. Such Oligomers may be prepared using methods such as those described in Lesnikowski et al., Nucleic Acids Research 18(8):2109-2115 (1990) and Stec et al., Nucleic Acids Research 19(21):5883-5888 (1991).

Synthetic methods for preparing methylphosphonate Oligomers are described in Lee B.L., et al., Biochemistry 27:3197-3203 (1988), and Miller, P.S., et al., Biochemistry 25:5092-5097 (1986), and commonly-assigned published PCT applications WO 92/07864 and WO 92/07882 the disclosures of which are incorporated herein by reference.

Also preferred are Oligomers which are nucleoside/non-nucleoside polymers. Suitable Oligomers also include chimeric oligonucleotides which are composite RNA, DNA analogues (Inoue et al., FEBS Lett. 2115:327 (1987)).

5 Other suitable Oligomers include Oligomers having chimeric backbones. Such chimeric backbone Oligomers include Oligomers having mixed phosphate backbones including nucleoside sequences which are capable of activating RNaseH and nucleoside sequences which do not activate

10 RNaseH, and thus allow site directed cleavage of an RNA molecule. See U.S. Patent No. 5,149,797 which is incorporated herein by reference. Chimeric backbone Oligomers also include Oligomers having a mixture of internucleosidyl linkages which may or may not include

15 phosphorus atoms, such as morpholinyl linkages, formacetal linkages, peptide nucleic acid (PNA) linkages and the like. Oligomers having a neutral backbone, for example, methylphosphonate Oligomers with cleaving or cross-linking moieties attached, may prove advantageous in certain

20 circumstances; such Oligomers may have a longer half-life in vivo since the neutral structure reduces the rate of nuclease digestion while the cleaving or cross-linking moiety may promote inactivation of target polynucleotide sequences.

25 According to one aspect of the present invention, these antisense Oligomers have a sequence which is complementary to a portion of the RNA transcribed from the selected target gene. Although the exact molecular mechanism of inhibition has not been conclusively

30 determined, it has been suggested to result from formation of duplexes between the antisense Oligomer and the RNA transcribed from the target gene. The duplexes so formed may inhibit translation, processing or transport of an mRNA sequence or may lead to digestion by the enzyme

35 RNaseH.

Single stranded Oligomers may also bind to a duplex DNA target such that a duplex is formed with one of the

two DNA strands, and the second DNA of the target strand is displaced from the duplex. Preferred is the formation of a duplex by the Oligomer with the coding strand of the DNA duplex target ("invading duplex"). The invading
5 duplex so formed may inhibit transcription.

According to an alternate aspect of the present invention, down regulation of 5-alpha reductase or the androgen receptor may be accomplished by triple helix formation using a Third Strand Oligomer or a Triplex
10 Oligomer Pair having sequences selected such that the Oligomer(s) are complementary to and form a triple helix complex with a target sequence of double stranded or single stranded nucleic acid and thereby interfere with or prevent expression of the targeted nucleic acid sequence.
15 Triple strand formation can occur in one of several ways. A single stranded Oligomer may form a triple strand with duplex DNA or RNA; two separate or connected Oligomers may form a triple strand with single stranded DNA or RNA; two separate or connected Oligomers may bind to one of the
20 duplex DNA or RNA strands and displace the other such that it is not involved in triple strand formation. Further descriptions of the use of Oligomers (including Third Strand Oligomers and Triplex Oligomer Pairs) to prevent or interfere with the expression of a target sequence of
25 double or single stranded nucleic acid by formation of triple helix complexes is described in the copending U.S. Patent Applications Serial Nos. 07/388,027, 07/751,813, 07/772,081 and 07/987,746, the disclosures of which are incorporated herein by reference.

30 As a general matter, the Oligomer employed will have a sequence that is complementary to the sequence of the target nucleic acid. However, absolute complementarity may not be required; in general, any Oligomer having sufficient complementarity to form a stable duplex (or
35 triple helix complex as the case may be) with the target nucleic acid is considered to be suitable. Since stable duplex formation depends on the sequence and length of the

SUBSTITUTE SHEET (RULE 26)

hybridizing Oligomer and the degree of complementarity between the antisense Oligomer and the target sequence, the system can tolerate less fidelity (complementarity) when longer Oligomers are used. This is also true with
5 Oligomers which form triple helix complexes. However, Oligomers of about 8 to about 40 nucleosidyl units in length which have sufficient complementarity to form a duplex or triple helix structure having a melting temperature of greater than about 40°C under physiological
10 conditions are particularly suitable for use according to the methods of the present invention.

The concentration of Oligomer used may vary, depending upon a number of factors, including the extent of hair loss condition to be treated, the type and the
15 specificity of the particular antisense Oligomer, Triplex Oligomer Pair, or Third Strand Oligomer selected. It is believed that significant inhibition as demonstrated by a cosmetically significant decrease in progression of hair loss may be obtained at concentrations in about the 10 μ M
20 range; however, under other conditions, higher or lower concentrations of Oligomer may be preferred.

Where Oligomers are to be administered transdermally, preferred are neutral Oligomers.

According to one preferred aspect, these Oligomers
25 may comprise a conjugate between a polynucleoside or nucleoside/non-nucleoside polymer and a conjugation partner. Suitable conjugation partners include intercalating agents such as acridine, alkylating agents, binding substances for cell surface receptors, lipophilic
30 agents, photo-crosslinking agents such as psoralen, other cross-linking agents, pro-chelates, or nucleic acid modifying agents, including groups capable of cleaving a targeted portion of a nucleic acid such as hydrolytic or nucleolytic agents like o-phenanthroline copper or EDTA-
35 iron, all of which may be incorporated in the Oligomers.

Conjugation partners may also be introduced into the Oligomer by the incorporation of modified nucleosides or

SUBSTITUTE SHEET (RULE 26)

nucleoside analogs through the use of enzymes or by chemical modification of the Oligomer, for example, by the use of non-nucleotide linker groups.

When used to prevent function or expression of a single or double stranded nucleic acid sequence, these Oligomers may be advantageously derivatized or modified to incorporate a nucleic acid modifying group which may be caused to react with said target nucleic acid and irreversibly modify its structure, thereby rendering it non-functional. Conjugates may be introduced to alter the pharmacodynamics or toxicity of the oligonucleotides in the body. For example, a cleavable moiety may be attached according to patent 4,588,525, such cleavable moiety being particularly useful with topical application of the conjugate. Upon application of the conjugate, that portion of conjugate that enters the blood stream instead of the tissue at the site of topical application is cleaved to a more highly charged species which only poorly enters non-target tissues and is readily excreted.

Commonly assigned USSN 565,299, the disclosure of which is incorporated herein by reference, discloses psoralen-derivatized Oligomers.

As discussed above, a wide variety of nucleic acid modifying groups may be used as conjugation partners to derivatize these Oligomers. Nucleic acid modifying groups include groups which, after the derivatized Oligomer forms a complex with a single stranded or double stranded nucleic acid segment, may be caused to cross-link, alkylate, cleave, degrade, or otherwise inactivate or destroy the target nucleic acid segment or a target sequence portion thereof, and thereby irreversibly inhibit the function and/or expression of that nucleic acid segment.

The location of the nucleic acid modifying groups in the Oligomer may be varied and may depend on the particular nucleic acid modifying group employed and the targeted nucleic acid segment. Accordingly, the nucleic

acid modifying group may be positioned at the end of the Oligomer or intermediate between the ends. A plurality of nucleic acid modifying groups may be included.

In one preferred aspect, the nucleic acid modifying group is photoreactable (e.g., activated by a particular wavelength, or range of wavelengths of light), so as to cause reaction and, thus, cross-linking between the Oligomer and the nucleic acid target.

Exemplary of nucleic acid modifying groups which may cause cross-linking are the psoralens, such as an aminomethyltrimethyl psoralen group (AMT). The AMT is advantageously photoreactable, and thus must be activated by exposure to particular wavelength light before cross-linking is effectuated. Other cross-linking groups which may or may not be photoreactable may be used to derivatize these Oligomers.

Alternatively, the nucleic acid modifying groups may comprise an alkylating agent group which is covalently bonded to the nucleic acid segment to render the target inactive. Suitable alkylating agent groups are known in the chemical arts and include groups derived from alkyl halides, haloacetamides and the like. Polynucleotide modifying groups which may be caused to cleave the polynucleotide segment include moieties which generate radicals, as well as moieties which promote cleavage through nucleophilic attack. Transition metal chelating complexes, such as ethylenediaminetetraacetate (EDTA) or a neutral derivative thereof, can be used to generate radicals. Other groups which may be used to effect radical mediated cleavage include phenanthroline, porphyrin and the like. When EDTA is used, iron may be advantageously tethered to the Oligomer to help generate the cleaving radicals. Although iron-EDTA is a preferred polynucleotide cleaving group, other nitrogen containing materials, such as azo compounds or nitrenes or other transition metal chelating complexes, may be used. Yet other cleavage agents include nucleophilic agents and

hydrolytic agents that promote the addition of water at the phosphorus internucleotide linkages. Such agents include amines, substituted guanidinium groups, imidazole groups and the like.

5 1. Preferred Neutral Oligomer Formulations

Preferred neutral Oligomers include neutral alkyl- and aryl-phosphonate Oligomers and neutral Oligomers comprising morpholino or phosphoramidate linkages. Especially preferred are neutral methylphosphonate
10 Oligomers. In view of their demonstrated ability to penetrate skin, including tape stripped skin, (which has had the stratum corneum removed and which has been reported as a model for mucous membrane), particularly preferred are neutral methylphosphonate Oligomers having
15 only methylphosphonate internucleosidyl linkages.

According to another aspect of the present invention, preferred are Oligomers which may be neutral until they enter cells and once inside are converted to charged species through chemical or biological processes. Such
20 charged oligonucleotides may contain other moieties that stabilize the oligonucleotides to nuclease degradation. Substituents such as 2'-O-methylribose groups, various base modifications, and analogs of the phosphorous backbone, such as phosphorothioates, can increase
25 resistance to nucleases. Additionally, the presence of methylphosphonate or other neutral internucleoside linkages in the Oligomer give exonuclease resistance.

Preferred are neutral Oligomers having from about 6 to about 40 nucleosides, more preferably from about 12 to
30 about 20 nucleosides. Although neutral Oligomers which comprise more than 20 nucleosides may be used, where complementarity to a longer sequence is desired, it may be advantageous instead to employ shorter neutral tandem Oligomers which total more than 20 nucleosides in order to
35 maximize solubility and penetration through the skin while competing for the development of a secondary structure of

the target nucleic acid, such as an mRNA. These tandem Oligomers may also increase specificity of binding to the target sequence. Alternatively, it may be advantageous to use a plurality of neutral Oligomers, each Oligomer complementary to a distinct target sequence which may be part of the same gene or a different gene.

Where the neutral Oligomers comprise alkyl- or aryl-phosphonate Oligomers, it may be advantageous to incorporate nucleoside monomeric units having modified ribosyl moieties. The use of nucleoside units having 2'-O-alkyl- or 2'-halo- and, in particular, 2'-O-fluoro- or 2'-O-methyl-ribosyl moieties in these neutral Oligomers may advantageously improve hybridization of the Oligomer to its complementary target sequence.

Suitable formulations comprise about 0.0001% to about 10% by weight of neutral Oligomer.

In one preferred aspect, there are provided neutral Oligomer formulations which comprise about 2% to about 100% of a short chain aliphatic alcohol. Suitable alcohols include ethanol, isopropyl alcohol, propylene glycol and glycerol. In certain studies, formulations of neutral Oligomers comprising ethanol have demonstrated advantageous transdermal flux.

In an especially preferred aspect, these neutral Oligomer formulations may additionally comprise a flux enhancer. Suitable flux enhancers include those known to those skilled in the art and include decylmethylsulfoxide, dimethylsulfoxide as well as cyclic ketones, lactones, anhydrides and esters such as those described in PCT Application No. PCT/US86/02583 (Publication Number W087/03473). Some of these flux enhancers also increase retention of the Oligomer and, thus, act to increase the concentration of Oligomer within the skin itself.

Thus, for Oligomer formulations for direct (local) treatment, such as topical application to skin, it is preferred to use a flux enhancer which not only maximizes transdermal flux, but increases Oligomer retention in the

skin. Certain cyclic ketone and lactone enhancers have been reported to increase local retention as well and, thus, comprise a preferred class of enhancers for topical administration of Oligomer formulations.

- 5 According to one aspect, the present invention includes liposomal delivery of the Oligomers. Various methods and types of liposomal vesicles for drug delivery have been described. See, e.g., Remington's Pharmaceutical Sciences (1990). The Oligomers may be
10 encapsulated by a liposome. Such liposome complexes advantageously may act to enhance delivery of Oligomer.

B. Preferred Target Genes and Target Sequences

- According to a preferred aspect, the present invention is directed to methods of preventing or reducing
15 hair loss using Oligomers which interfere with the expression of the enzyme 5-alpha-reductase, or with the expression of the androgen receptor itself. Suitable Oligomers include antisense Oligomers, Third Strand Oligomers and Triplex Oligomer Pairs.

- 20 According to one aspect of the present invention, there are provided methods of decreasing hair loss by preventing or interfering with the expression of the human androgen receptor or the 5-alpha-reductase enzyme by administration of an Oligomer which is complementary to a
25 target sequence on the DNA or an mRNA transcribed therefrom which codes for the androgen receptor or 5-alpha-reductase or to a sequence immediately upstream from the transcription start site for the mRNA. The Oligomer administered may be either an antisense Oligomer,
30 a Third Strand Oligomer, or a Triplex Oligomer Pair. The antisense Oligomer is complementary to a sequence of RNA transcribed from a target gene, to a single-stranded DNA target sequence, or to a single RNA or DNA strand contained within a duplex. The Third Strand Oligomer has
35 a base sequence selected so that it is capable of hydrogen bonding with a sequence of a double stranded nucleic acid

and forming a triple helix complex therewith. The first and second Oligomers of the Triplex Oligomer Pair have sequences selected such that they are complementary to and capable of hydrogen bonding with a targeted
5 single-stranded nucleic acid sequence of a target gene or its transcription product or to a single strand of a duplex and together with the single stranded nucleic acid form a triple helix complex.

The target gene is selected from the group consisting
10 of those genes encoding the androgen receptor or the enzyme 5-alpha-reductase and is considered to include a target sequence immediately upstream from the transcription start site of that gene. Preferably the target sequence would include sequences from -500 to +20
15 (relative to the transcription start site) of the androgen receptor gene or 5-alpha reductase gene. More preferably suitable sequences would include target sequences in the area from -100 to +20 (relative to the transcription start site) of the androgen receptor gene or 5-alpha reductase
20 gene.

Oligomers of appropriate length, preferably from about 8 to 40 nucleosides, more preferably from about 12 to about 20 nucleosides, are selected so as to be adjacent to or cover these sites when hybridized to the target, in
25 part or in whole. Preferred sites when the target sequence is mRNA include, in both the androgen receptor and 5-alpha-reductase genes, the 5' untranslated region, the translation initiation region including regions slightly downstream of the AUG start codon (preferably up
30 to about 20 nucleotides downstream from the AUG initiation codon), splice acceptors, splice donors, and the 3' untranslated region.

As examples, in the case of the androgen receptor, the preferred target sites would include the sequence
35 ranging from 18-50, with reference to the nucleotide positions of the human androgen receptor gene (Genbank

SUBSTITUTE SHEET (RULE 26)

locus:HUMARB). A preferred target of this sequence range would include the sequence:

[1] TTC CCC CAC TCT CTC TC,

corresponding to the nucleotide positions 28-44 of the
5 androgen receptor gene (Genbank locus:HUMARB). A second preferred target of this sequence ranging would include the sequence:

[2] CTC TCT CTC ACC TC,

corresponding to the nucleotide positions 36-50 of the
10 androgen receptor gene. A preferred triplex target site would include the sequence range from 109-126 of exon 4 of the human androgen receptor gene (Genbank locus:HUMARC4). A preferred target of this sequence range would include the sequence:

15 [3] UCU CUC UUC CUU CCC, o

corresponding to the nucleotide positions 109-123 of exon 4 of the human androgen receptor gene.

Thus, according to a preferred aspect of the present invention, Oligomers of the appropriate length, preferably
20 from about 8 to 40 nucleosides and more preferably from about 12 to about 25 nucleosides especially from about 12 to about 20 nucleosides, are selected so as to have sequences which hybridize to sites immediately adjacent to these sites or hybridize with and cover these sites, in
25 part or wholly, as defined by the nucleotide positions included above for 5-alpha-reductase and the androgen receptor.

When antisense Oligomers are used, the sequence of the Oligomers is the reverse complement of the sequence of
30 the targeted region so as to be able to hybridize to the targeted region.

When Third Strand Oligomers are used, the Oligomers are selected to form sequence-specific hydrogen bonding interactions with the double stranded nucleic acid target.

35 When Triplex Oligomer Pairs are used, the first and second Oligomers are selected so as to form sequence specific hydrogen bonding interactions with a single

SUBSTITUTE SHEET (RULE 26)

stranded nucleic acid, and together form a triple helix structure.

To assist in understanding the present invention, the following examples are included which describe the results of a series of experiments. The following examples relating to this invention should not, of course, be construed in specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the present invention as hereinafter claimed.

Example 1

Preparation of Oligoribonucleosides

Oligoribonucleotides may be synthesized using the following procedures:

The oligoribonucleotides were synthesized using 5'-O-dimethoxytrityl-2'-O-tert-butyldimethylsilyl-3'-O-N,N-diisopropyl- β -cyanoethylphosphoramidite nucleosides (purchased from either Millipore or Peninsula Laboratories). The syntheses were done on a 1 μ mole scale with a Milligen 8750 automated DNA synthesizer using standard Milligen phosphoramidite procedures with the exception that the coupling times were extended to 12 minutes to allow adequate time for the more sterically hindered 2'-O-tert-butyldimethylsilyl RNA monomers to react. The syntheses were begun on control-pore glass bound 2'-O-tert-butyldimethylsilyl ribonucleosides purchased from Peninsula Laboratories. All other oligonucleotide synthesis reagents were as described in Milligen's standard protocols.

After synthesis, the oligonucleotides were handled under sterile, RNase-free conditions. Water was sterilized by overnight treatment with 0.5% diethylpyrocarbonate followed by autoclaving. All glassware was baked for at least 4 hours at 300°C.

SUBSTITUTE SHEET (RULE 26)

The oligonucleotides were deprotected and cleaved from the support by first treating the support bound oligomer with 3/1 ammonium hydroxide/ethanol for 15 hours at 55°C. The supernatant, which contained the oligonucleotide, was then decanted and evaporated to dryness. The resultant residue was then treated with 0.6 mL of 1 M tetrabutylammonium fluoride in tetrahydrofuran (which contained 5% or less water) for 24 hours at room temperature. The reaction was quenched by the addition of 0.6 mL of aqueous 2 M triethylammonium acetate, pH 7. Desalting of the reaction mixture was accomplished by passing the solution through a Bio-Rad 10DG column using sterile water. The desalted oligonucleotide was then dried.

Purification of the oligoribonucleotides was carried out by polyacrylamide gel electrophoresis (PAGE) containing 15% 19/1 polyacrylamide/bis-acrylamide and 7 M urea using standard procedures (See Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, pages 184-185 (Cold Spring Harbor 1982)). The gels were 20 cm wide by 40 cm long and 6 mm in width. The oligoribonucleotides (60 OD Units) were dissolved in 200 μ L of water containing 1.25% bromophenol blue and loaded onto the gel. The gels were run overnight at 300 V. The product bands were visualized by UV backshadowing and excised, and the product eluted with 0.5 M sodium acetate overnight. The product was desalted with a Waters C18 Sep-Pak cartridge using the manufacturer supplied protocol. The product was then ³²P labelled by kinasing and analyzed by PAGE.

Example 2

Thermal denaturation profiles

The stabilities of triple stranded complexes formed between two MP oligomers and a complementary RNA oligomer were determined by thermal denaturation analysis. Solutions were prepared for analysis as follows: 2.4 μ M MP oligomer, 1.2 μ M RNA oligomer (2:1 mole ratio MP:RNA) in 10 mM potassium phosphate, 0.1 M sodium chloride, 0.03%

potassium sarkosylate, 0.1 mM EDTA, pH 7.2, final volume = 1 mL. Each solution was heated to 80°C and allowed to cool to 4°C over a period of about 4 hours. The solutions were then transferred to quartz cuvettes (1 cm pathlength) and placed in a Varian Model 3E spectrophotometer equipped with a temperature control module interfaced to an IBM compatible PC computer. Temperature was varied from 5°C to 80°C at a rate of 1.5 °C/minute and absorbance was measured continuously at 260 nm. Plots of A_{260} versus temperature revealed single monophasic transitions for each of the oligomer sets described in this example.

The melting temperatures (T_m) at which half of each complex had dissociated to single strands was 45.8°C and 42.3°C (2:1 mole ratio MP:RNA) for Oligomer 1 and Oligomer 2, respectively (see Table I). The entire melting curve for MP Oligomer 2 and its target at 2:1 and 1:1 ratios is shown in Figure 1. Thus, above 2.4 micromolar MP oligomer concentration at physiological temperatures (below 37°C in human skin) these Oligomers would be substantially hybridized.

Figure 1 depicts a thermodenaturation profiles for double-stranded and triple-stranded complexes formed between Oligomer 2 and a target sequence.

Table I

<u>Oligomer</u>	<u>T_m (°C)</u>	(MP:RNA mole ratio)
[4] Oligomer 1 (Androgen Rec. #1 target: 5' gag-aga-gag-tgg-ggg-aa)	44.1°C 45.8°C	(1:1) (2:1)
[5] Oligomer 2 (Androgen Rec. #2 target: 5' gag-gtg-gag-aga-gag)	41.1°C 42.3°C	(1:1) (1:2)

Example 3

Clearance of Methylphosphonate Oligomer From Serum

Clearance of methylphosphonate oligomers from mouse serum was measured with two oligomers: ^3H -tetramer (1689-3)

SUBSTITUTE SHEET (RULE 26)

^3H -(dT)₄ and a 12-mer (2054-2) ^3H -C2-(TC)₆ (where C2 referred to a 2-carbon non-nucleotide linker with a primary amine).

BALB/C female mice (Jackson Laboratory) 9-10 weeks old were injected in the tail vein with 27 nmol (3×10^5 dpm) of oligomer in 200 μl phosphate buffered saline.

Samples were collected at the indicated times by eye bleed. 100 μl samples were collected in 200 μl heparinized eye bleed capillary tubes. The mice were mildly anesthetized with metofane (methoxyflurane) during the procedure, and each mouse was bled no more than 7 or 8 times. The blood was transferred to polypropylene microcentrifuge tubes and spun to remove cells. A 20 μl aliquot of the serum was removed and combined with 5 ml of scintillation fluid (ScintiVerse BD). The amount of radioactivity was determined in a liquid scintillation counter.

The plasma half-lives of both oligomers in mice were found to be approximately 8 to 10 minutes. Figures 2 and 3 depict plots of the clearance from plasma of the 4-mer (Figure 2) and the 12-mer (Figure 3).

Example 4

Preparation of Skin Samples for Permeability and Tissue Level Studies

25 A. Hairless Mouse Skin

Hairless mice (male, HRS/J strain, 8 to 10 weeks old, 20 to 25 g) were sacrificed in a CO₂ chamber and approximately 5 cm² of full-thickness skin (dermis and epidermis) was removed from the abdomen. After removal of the subcutaneous fat, the skins were rinsed with physiological saline and used within one hour.

The stratum corneum was removed from hairless mice for permeability experiments by using cellophane tape. The tape was gently applied to the skin of a recently sacrificed animal and then pulled away from the body.

SUBSTITUTE SHEET (RULE 26)

This was repeated 12 to 15 times with fresh pieces of tape.

B. Human Cadaver Skin

Human cadaver skin was obtained at autopsy through the Stanford University Medical Center. The skin was excised using a dermatome from the thigh area of a 74 year old male within 24 hours post-mortem. The thickness, as measured with a Van Keuren light wave micrometer, ranged from 125 to 450 μm . The average thickness was 200 to 300 μm . The skin was rinsed with phosphate buffered saline (pH 7.4), blotted dry and frozen for 6 months in triple-sealed bags evacuated of air. Prior to use, the skin was thawed and rinsed in PBS.

Example 5

15 Permeability Experiments

A diffusion console containing nine glass Franz diffusion cells was used in the permeability experiments. The Franz cells were maintained at 37°C by thermostatically controlled water, which was circulated through a jacket surrounding the cell body. Each skin was mounted and clamped between the cell body and the cell cap so that the epidermal side faced upward (vehicle side). The skins were then allowed to equilibrate for 1 hour in the diffusion cells prior to addition of the vehicle. The exposed surface was 2.0 cm^2 . The receptor was 0.01 M phosphate-buffered saline (pH 7.4) isotonic saline with 0.05% sodium azide added to prevent growth of microorganisms.

The Franz cells were closed to maximize drug concentration in the receptor phase. The volume of the cells was 6.2 mL. The cells were stirred using a teflon-coated stir bar at 600 rpm.

The drug/vehicle mixtures were pipetted through the cell cap onto the skin [0.2 mL total vehicle added to 2.0 cm^2 (0.1 nK. cm^2)]. At certain times following addition of the vehicles, a syringe needle was inserted through the

SUBSTITUTE SHEET (RULE 26)

side arm into the receptor solution and 300 μ L was withdrawn. The volume removed was replaced by an equal volume of fresh saline. The solution effect was accounted for in the drug flux calculations.

5 Permeability results are tabulated in Table II.

Example 6

Chromatographic Analysis of Oligomer

The 14-mer (neutral methylphosphonate Oligomer of 14 nucleosides having only methylphosphonate internucleosidyl linkages) and 14-mer-IA (methylphosphonate Oligomer of 14 nucleosides having an internal anionic internucleosidyl linkage) were measured in the receptor solution by HPLC. These analyses were performed on a Waters 840 system consisting of two model 510 pumps, a model 481 UV detector, a model 710B WISP sample processor, and a Digital computer model 350 microprocessor/programmer.

A. 14-Mer

The column used to separate the 14-mer was a 3.9 mm x 15 cm 4 μ m, Waters Nova-Pak C18. A gradient elution was performed as follows for the 14-mer:

	<u>Time (min)</u>	<u>%A</u>	<u>%B</u>
	0	100	0
	4	70	30
	10	55	45
25	11	55	45
	12	5	95
	15	5	95
	17	100	0
	22	100	0

30 Flow rate = 1.1 mL/min, wavelength = 260 nm, retention time = 9.6 min.

A = 0.05 M TEAA, pH 7.6

B = acetonitrile/A (75:25)

SUBSTITUTE SHEET (RULE 26)

B. 14-Mer-IA

The HPLC conditions were altered somewhat for measurement of the 14-mer-IA. Again, a gradient elution profile was used as described below.

5	<u>Time (min)</u>	<u>%A</u>	<u>%B</u>
	0	0	100
	5	28	72
	14	45	55
	14.2	45	55
10	15.5	98	2
	20	98	2
	22	0	100
	28	0	100

Flow rate = 1.1 mL/min, wavelength = 260 nm, retention

15 time = 10.2 min.

A = Acetonitrile/B (75:25)

B = 0.05 M ammonium acetate, pH 7.4

Example 7Tissue Level Measurements of Oligomer Retained in Skin

20 Preliminary work was performed to determine the amount of 14-mer oligomer retained in the skin samples at the conclusion of the permeability experiments. The skins were rinsed with a small amount of water for several seconds, followed by washing for about 10 seconds with a
25 small amount of acetonitrile to remove solid drug from the surface of the skin. The skins were then rinsed for several seconds with water. The skins were then frozen until analysis (up to several weeks). The skins were thawed and the region not exposed to the donor vehicle was cut away
30 and discarded. The hydrated skin samples were weighed and then homogenized in 0.01 M sodium phosphate, pH 7.4, using a Polytron Homogenizer for approximately 2 minutes. The homogenate was then centrifuged at 8,000 g for 15 minutes at room temperature. The supernatant was removed and
35 analyzed directly by HPLC analysis (see below for conditions).

SUBSTITUTE SHEET (RULE 26)

The chromatographic conditions were similar to those described above for the 14-mer in permeability experiments with some minor changes noted below.

	<u>Time (min)</u>	<u>%A</u>	<u>%B</u>
5	0	100	0
	5	70	30
	14	55	45
	15.5	2	98
	32	2	98
10	35	100	0
	42	100	0

Flow rate = 1.1 mL/min, wavelength = 260 nm, retention time = 11.1 min.

A = 0.05 M ammonium acetate, pH 7.0

15 B = acetonitrile/A (75:25)

Presence of the oligomer in the tissue homogenates was confirmed by spiking the samples with 40 μ L of a 1.8 μ g/mL solution of 14-mer.

20 Resuspension of the pellet obtained after centrifugation, followed by homogenization and recentrifugation, led to release of between 1 to 3% of the total 14-mer recovered from the original sample. These results indicate that the 14-mer was efficiently isolated in the first extraction step.

25 Amounts of Oligomer isolated from skin after permeability experiments using different vehicles are tabulated in Table III.

Example 8

Measurement of Flux and Retention of Oligomers in Human

30 Skin

Human skin which had been dermatomed to a thickness of about 5-200 μ m was used. The skin was mounted in a closed glass Franz diffusion cell (as described in Example 5).

SUBSTITUTE SHEET (RULE 26)

Vehicle containing oligomer and, in some instances, enhancer ($100 \mu\text{L}/\text{cm}^2$) was placed on the surface of the skin (2 cm^2 exposed surface).

The amount of oligomer diffusing through and remaining in the skin was measured by HPLC. (See Example 5).

Results are summarized in Table IV. Ethanol alone was found to be an effective penetration enhancer. Addition of DMS (decylmethylsulfoxide) to ethanol generally increased the penetration rate (and cumulative amount, i.e. amount penetrated over 24 hour period) of the 6-, 10- and 14-mers through human skin relative to that from ethanol alone. Addition of water to the ethanol/DMS vehicle increased the flux (and cumulative amount) still further for the 6-mer; however, flux (and cumulative amount) for the 10-mer and 14-mer was reduced.

Addition of DMS to propylene glycol increased the flux (and cumulative amount) of the 6-mer through human skin; however, the flux (and cumulative amount) was still an order of magnitude lower compared with the ethanol/DMS vehicle. Removing the stratum corneum from human skin led to a large increase in flux (and cumulative amount) of the 6-mer, although the increase was not as dramatic as that observed with hairless mouse skin.

In comparing the cumulative amount data from hairless mouse skin with human skin for the 10-mer and the 14-mer, the cumulative amount was greater in hairless mouse skin, but was generally within an order of magnitude.

Overall, an inverse relationship of permeation rate with molecular weight was observed (i.e., the higher the molecular weight, the lower the cumulative amount).

Generally, the highest retention of oligomer both in the viable tissues (dermal layer) and stratum corneum was observed from the ethanol/water/DMS vehicle. The ratio of retained oligomer in stratum corneum to dermis was about 10:30 (Note: Since there was considerably more viable tissue than stratum corneum, the majority of oligomer retained was in the dermis). Tape stripping (to remove

stratum corneum) of skin did not lead to a larger amount of 6-mer being retained in dermis as compared to retention in dermis using whole skin.

5 Table V reports retention of 14-mer in dermis versus stratum corneum after treatment with 14-mer in various vehicle/enhancer combinations. Stratum corneum and dermis were separated before analysis by microwave treatment as described by Kumar et al. (Pharm. Res. 6:740-741 (1989)).

o

TABLE II
Permeability of Oligomers in Hairless Mouse (HM)
and Human Skin (HS)

	Skin	Oligomer	Donor Vehicle ^a	Cumulative Amount at 24 h ($\mu\text{g}/\text{cm}^2$)
5	HM	14-mer	H ₂ O	0.75
			EtOH	0.28
			EtOH/DMS (95:5)	5.5
			EtOH/DMS (97.5:2.5)	4.4
			EtOH/OA (95:5) ^b	0.30
			EtOH/OA (97.5:2.5)	0.24
			EtAc ^c	1.2
			EtAc/DMS (95:5)	1.1
			EtAc ₄ /OA (95:5)	0.60
			EtOH ^d	187
			EtOH/DMS (95:5) ^d	186
			EtOH/H ₂ O/DMS (80:15:5)	3.5
			EtOH/H ₂ O/DMS (80:15:5) ^e	2.7
			EtOH/H ₂ O/DMS (80:15:5) ^f	2.1
			EtOH/H ₂ O/DMS (80:15:05) ^g	0.23
	HM	14-mer-IA	H ₂ O	0
			EtOH	0
			EtOH/DMS (95:5)	0.61
	HS	14-mer	EtOH	0.26
			EtOH/DMS (95:5)	0.24
			EtOH/OA (95:5)	0.30
			EtOH/H ₂ O/DMS (80:15:5) ^h	0.23

^aUnless stated in the table footnotes, all the donor vehicles were saturated with oligomer

10 ^bOA = oleic acid

^cEtAc = ethylacetate

^dThese skins were free of stratum corneum, which was removed by tape stripping.

15 ^e14-mer concentration in the vehicle was 1.0 mg/mL (below saturation)

^f14-mer concentration in the vehicle was 0.5 mg/mL (below saturation)

⁹14-mer concentration in the vehicle was 0.05 mg/mL (below saturation)

^h14-mer concentration in the vehicle was 1.0 mg/mL (below saturation)

5

TABLE III

A. Amounts of 14-mer Recovered from Skin Samples

Skin	Donor Vehicle	$\mu\text{g/gm}^a$	μM^b
<u>HM</u>	EtOH/DMS (95:5)	30.2	7.1
	EtOH/DMS (95:5) ^c	112	26.3
	EtOH/H ₂ O/DMS (80:15:5)	77	17.9
	EtOH/H ₂ O/DMS (80:15:5) ^d	18.4	4.3
HS	EtOH/DMS (95:5)	67.1	15.7

10 ^aTotal μg of 14-mer recovered from the homogenized skin sample corrected for loss of 14-mer during homogenization and centrifugation (see Example 6); the gm is the wet weight of the skin as measured prior to homogenization

15 ^b μM concentration of 14-mer in the skin were obtained from the molecular weight of the 14-mer and the assumed density of 1.0 for the skin sample (i.e., 1.0 gm of skin is equal to 1.0 cc of skin)

^cThe HM skin used in this experiment was stripped to remove the stratum corneum

20 ^dThe concentration of 14-mer in this vehicle was 0.5 mg/mL compared to all the other experimental vehicles, which were saturated with excess solid 14-mer

B. Retention of 14-mer in Whole Skin and Viable Tissues^a

Skin	Section	Donor Vehicle	$\mu\text{g/gm}^b$	μM^c
5	HM Whole	EtOH/H ₂ O/DMS (80:15:5)	63.2	14.8
	Viable ^d	EtOH/H ₂ O/DMS (80:15:5)	35.2	8.2
HS	Whole	EtOH/H ₂ O/DMS (80:15:5)	105.9	24.7
	Viable ^d	EtOH/H ₂ O/DMS (80:15:5)	7.0	1.6

^aThe weighed skin samples (hydrated) were either homogenized whole or the stratum corneum was removed, and the 14-mer content of the remaining tissue (viable epidermis and dermis) was determined. In each case, n = 2.

^bTotal μg of 14-mer recovered from the homogenized skin sample corrected for loss of 14-mer during homogenization and centrifugation (see Example 6); the gm is the wet weight of the skin as measured prior to homogenization

^c μM concentration of 14-mer in the skin were obtained from the molecular weight of the 14-mer and the assumed density of 1.0 for the skin sample (i.e., 1.0 gm of skin is equal to 1.0 cc of skin)

^dThe viable tissue is the tissue after the stratum corneum has been removed by microwave treatment (Kumar, et al., Pharm. Res. 6:740-741 (1989)). It is a combination of the viable epidermis and the dermis.

TABLE IV
Penetration of Oligomers Through Skin

<u>A. Human Skin</u>					
	<u>Vehicle/</u>	<u>Ratio of</u>	<u>24Hr Cumulative Values:</u>		
5	<u>Enhancer</u>	<u>Components</u>	<u>nmoles/cm2 Mean and SD</u>		
			<u>6 Mer</u>	<u>10 Mer</u>	<u>14 Mer</u>
	EtOH/H ₂ O/DMS	(80:15:5)	13.8 (5.7)	0.94 (1.3)	0.18 (0.17)
			2.2 (2.0)		
	EtOH/DMS	(95:5)	8.2 (5.4)	6.0 (4.2)	0.83 (1.0)
10	EtOH	(100:0)	3.4 (2.8)	4.0 (6.7)	0.37 (0.48)
	PG	(100:0)	0.21 (0.37)	No Data	No Data
	PG/DMS	(95:5)	0.57 (0.50)	No Data	No Data
	EtOH/DMS	(95:5)	34.0 (4.8)	No Data	No Data
	(Tape Stripped)				
15	The second value for the 6Mer came from a time study using a different skin donor, otherwise the data for the first three enhancers came from the same donor. The data for the last three enhancers came from the same experiment but from a different donor.				
20	<u>B. Hairless Mouse</u>				
	<u>Vehicle/</u>	<u>Ratio of</u>	<u>24Hr Cumulative Values:</u>		
	<u>Enhancer</u>	<u>Components</u>	<u>nmoles/cm2 Mean and SD</u>		
			<u>6 Mer</u>	<u>10 Mer</u>	<u>14 Mer</u>
	EtOH/H ₂ O/DMS	(80:15:5)	No Data	2.08 (0.82)	0.82
25	EtOH/DMS	(95:5)	No Data	1.94 (0.22)	1.28
	EtOH	(100%)	No Data	0.35 (0.10)	0.065

5

TABLE V
OLLIGOMERS IN HUMAN SKIN 1-24 HOURS

Her	Vehicle/Enhancer	Ratio of Components	Dermis µg In Wet Skin Mean (S.D.)	Stratum Corneum µg In Wet Skin Mean (S.D.)	Ratio of SC:Dermis
6 Her	EtOH/H ₂ O/DMS EtOH/DMS EtOH	(80:15:5) (95:5) (100:0)	66 (78) 12 (8) 6 (1)	1020 (1320) 190 (30) 88 (65)	13.8 (2.6) 28.6 (29.8) 13.4 (9.1)
10 Her	EtOH/H ₂ O/DMS EtOH/DMS EtOH	(80:15:5) (95:5) (100:0)	3 (2) 11 (2) 6 (4)	72 (39) 260 (280) 780 (1190)	23.8 (11.6) 30.2 (18.6) 236 (376)
14 Her	EtOH/H ₂ O/DMS EtOH/DMS EtOH	(80:15:5) (95:5) (100:0)	86 (1 Value) 6 (2) 5 (4)	70 (78) 150 (120) 160 (180)	18.6 22.7 (14.9) 62.8 (92.2)
6 Her	EtOH/DMS (TS) ^a PG PG/DMS	(95:5) (100:0) (95:5)	72 (14) 6 (6) 6 (3)	Tape Stripped 47 (10) 128 (4)	Tape Stripped 13.1 (10.5) 24.3 (11.1)
6 Her	EtOH/H ₂ O/DMS 10 minutes 1 hour 3 hour 8 hour 24 hour	(80:15:5)	Mean (A.D.) ^a 8 (1 Value) 7 (0.5) 9 (0.9) 6 (3) 16 (7)	Mean (A.D.) ^a 6 (1 Value) 60 (10) 120 (20) 130 (40) 1360 (1040)	Mean (A.D.) ^a 8.5 (1 Value) 9.3 (0.7) 12.6 (0.6) 41.3 (6.1) 59.2 (8.6)
6 Her	EtOH/Azone EtOH/GMO EtOH/H ₂ O/GMO	(95:5) (95:5) (80:15:5)	2 (2) 4 (1) 6 (1)	10 (2) 9 (1) 48 (5)	6.2 (2.8) 2.5 (0.9) 7.8 (0.9)

With the exception of the time study data for the 6Her, the values in this table are the means of three values from three separate cells, with the SD in parentheses. The 6 Her time study had one cell for the 30 minute point and 2 cells for the other time points. A.D. is the average deviation. ^aTS-tape stripped skin (stratum corneum removed.)

Claims

1. A method of decreasing androgen-associated hair loss by decreasing levels of protein-bound 5-alpha-dihydrotestosterone present in scalp tissue without
5 significantly interfering with testosterone metabolism in other tissues which comprises exposing scalp cells to an effective amount of an Oligomer or Oligomers which interact with a gene coding for androgen receptor or 5-alpha-reductase or its transcription product or a target
10 sequence immediately upstream from the transcription start site of said gene and thereby inhibits or alters expression of the androgen receptor or 5-alpha-reductase.
2. A method according to claim 1 wherein said Oligomer or Oligomers specifically recognize a target
15 sequence which comprises (a) single stranded RNA or DNA, (b) double stranded DNA or RNA, (c) a DNA/RNA duplex or (d) a single RNA or DNA strand contained within a duplex and wherein said Oligomer interferes with transcription or translation of the target sequence.
- 20 3. A method according to claim 2 wherein the rate of hair loss is decreased at least about 10 percent.
4. A method according to claim 2 wherein said Oligomer or Oligomers are substantially neutral.
5. A method according to claim 4 wherein protein-
25 bound 5-alpha-dihydrotestosterone comprises androgen receptor-bound 5-alpha-dihydrotestosterone.
6. A method according to claim 5 wherein said Oligomer or Oligomers comprise from about 8 to about 40 nucleosides.

SUBSTITUTE SHEET (RULE 26)

7. A method according to claim 5 wherein said Oligomers or Oligomers comprise tandem Oligomers totaling from about 20 to about 40 nucleosides per tandem group.

8. A method of decreasing androgen-associated hair
5 loss by decreasing levels of protein-bound 5-alpha-dihydrotestosterone in scalp tissue without significantly interfering with testosterone metabolism in other tissues which comprises exposing scalp cells to an amount of an Oligomer or Oligomers sufficient to decrease protein-bound
10 5-alpha-dihydrotestosterone in said scalp cells and give a decrease in rate of hair loss whereby said Oligomer or Oligomers specifically recognize a nucleic acid target sequence selected from (a) single stranded RNA or DNA (b) double stranded DNA or RNA, (c) a DNA/RNA duplex, or (d)
15 a single RNA or DNA strand contained within a duplex whereby the Oligomer or Oligomers selectively interfere with transcription or translation of the nucleic acid target sequence and wherein said nucleic acid target sequence comprises a gene coding for the androgen receptor
20 or 5-alpha-reductase or a transcription product thereof or a sequence immediately upstream from the transcription start site of the gene.

9. a method according to claim 8 wherein when said target sequence is (a) single stranded RNA or DNA or (b)
25 a single RNA or DNA strand contained within a duplex, the Oligomer or Oligomers are an antisense Oligomer or a Triplex Oligomer Pair.

10. A method according to claim 8 wherein when said target sequence is (a) double stranded DNA or RNA or (b)
30 a DNA/RNA duplex, the Oligomer is a Third Strand Oligomer.

11. A method according to claim 8 wherein said Oligomer or Oligomers are substantially neutral.

SUBSTITUTE SHEET (RULE 26)

12. A method according to claim 11 wherein protein-bound 5-alpha-dihydrotestosterone comprises androgen receptor-bound 5-alpha-dihydrotestosterone.

13. A method according to claim 12 wherein said
5 Oligomer or Oligomers comprise from about 8 to about 40 nucleosides.

14. A method according to claim 12 wherein said Oligomers or Oligomers comprise tandem Oligomers totaling from about 20 to about 40 nucleosides per tandem group.

10 15. A method of treating androgen-associated hair loss by decreasing levels of protein-bound 5-alpha-dihydrotestosterone present in scalp tissue without significantly interfering with testosterone metabolism in other tissues which comprises exposing scalp cells to an
15 amount of an Oligomer sufficient to decrease protein-bound 5-alpha-dihydrotestosterone in said scalp cells to produce a decrease in rate of hair loss wherein said Oligomer is selected from (a) an antisense Oligomer having a sequence complementary to a sequence of RNA transcribed from a
20 target gene present in the cells; (b) an antisense Oligomer having a nucleoside sequence complementary to a single stranded DNA target sequence; (c) an antisense Oligomer having a nucleoside sequence complementary to a single RNA or DNA strand contained within a duplex; (d) a
25 Third Strand Oligomer having a sequence complementary to a selected double stranded nucleic acid sequence of a target sequence present in the cells; and (e) a Triplex Oligomer Pair which is complementary to a single stranded nucleic acid sequence of a target gene or its transcrip-
30 tion product or to a single strand of a duplex and wherein said target gene is selected from the group consisting of those genes encoding 5-alpha-reductase and the androgen receptor or a sequence immediately upstream from the transcription start site of said gene.

SUBSTITUTE SHEET (RULE 26)

16. A method according to claim 15 wherein said Oligomer is substantially neutral.

17. A method according to claim 15 whereby the rate of hair loss is decreased by at least about 10 percent.

5 18. A method according to claim 15 wherein said protein-bound 5-alpha-dihydrotestosterone comprises androgen receptor-bound 5-alpha-dihydrotestosterone.

19. A method according to claim 18 wherein said Oligomer is complementary to a sequence corresponding to
10 a 5'-untranslated region, a translation initiation region, a 3'-untranslated region, a splice donor site or a splice acceptor site of a transcription product of said target gene.

20. A method according to claim 19 wherein said
15 Oligomer is a substantially neutral Oligomer.

21. A method according to claim 20 wherein protein-bound 5-alpha-dihydrotestosterone comprises androgen receptor-bound 5-alpha-dihydrotestosterone.

22. A method according to claim 21 wherein said
20 Oligomer or Oligomers comprise from about 8 to about 40 nucleosides.

23. A method according to claim 21 wherein said Oligomers or Oligomers comprise tandem Oligomers totaling from about 20 to about 40 nucleosides per tandem group.
25

24. A method according to claim 20 wherein said Oligomer comprises from about 12 to about 25 nucleosides.

25. A method of treating androgen-associated hair loss which comprises:

SUBSTITUTE SHEET (RULE 26)

exposing scalp to a hair loss rate diminishing amount of an Oligomer selected from (a) an antisense Oligomer having a sequence complementary to a sequence of RNA transcribed from a gene for the androgen receptor or (b)
5 an antisense oligomer having a sequence complementary to a sequence of RNA transcribed from a gene for 5- α -reductase.

26. A method of claim 25 wherein said Oligomer is a substantially neutral Oligomer.

10 27. A method according to claim 26 wherein said Oligomer is complementary to a 5'-untranslated region, a translation initiation region a 3'-untranslated region, a splice donor site, or a splice acceptor site of said RNA.

28. A method according to claim 27 wherein said
15 Oligomer comprises from about 12 to about 25 nucleosides.

29. A method of decreasing levels of protein-bound 5-alpha-dihydrotestosterone in a selected tissue without significantly interfering with testosterone metabolism in other tissues or systemically which comprises exposing
20 cells of the selected tissue with an effective amount of an Oligomer and Oligomers which interact with a gene coding for androgen receptor or 5-alpha-reductase or its transcription product or a target sequence immediately upstream from the transcription start site of said gene
25 and thereby inhibit or alter expression of the androgen receptor or 5-alpha reductase.

30. A method according to claim 29 wherein said Oligomer or Oligomers specifically recognize a target sequence which comprises (a) single stranded RNA or DNA,
30 (b) double stranded DNA or RNA, (c) a DNA/RNA duplex or (d) a single RNA or DNA strand contained within a duplex

SUBSTITUTE SHEET (RULE 26)

and wherein said Oligomer interferes with transcription or translation of the target sequence.

31. A method according to claim 30 wherein the rate of hair loss is decreased at least about 10 percent.

5 32. A method according to claim 30 wherein said Oligomer or Oligomers are substantially neutral.

33. A method according to claim 32 wherein protein-bound 5-alpha-dihydrotestosterone comprises androgen receptor-bound 5-alpha-dihydrotestosterone.

10 34. A method according to claim 33 wherein said Oligomer or Oligomers comprise from about 8 to about 40 nucleosides.

35. A method according to claim 33 wherein said Oligomers or Oligomers comprise tandem Oligomers totaling
15 from about 20 to about 40 nucleosides per tandem group.

36. A pharmaceutical composition comprising an amount of an Oligomer effective to diminish rate of androgen-associated hair loss wherein said Oligomer is selected from (a) an antisense Oligomer having a sequence
20 complementary to a sequence of RNA transcribed from a target gene present in the cells; (b) an antisense Oligomer having a nucleoside sequence complementary to a single stranded DNA target sequence; (c) an antisense Oligomer having a nucleoside sequence complementary to a
25 single RNA or DNA strand contained within a duplex; (d) a Third Strand Oligomer having a sequence complementary to a selected double stranded nucleic acid sequence of a target gene present in the cells; and (e) a Triplex Oligomer Pair which is complementary to a single stranded
30 nucleic acid sequence of a target gene or its transcription product or to a single strand of a duplex

SUBSTITUTE SHEET (RULE 26)

and wherein said target gene is selected from the group consisting of those genes encoding 5-alpha-reductase and the androgen receptor or a sequence immediately upstream from the transcription start site of said gene and a
5 pharmaceutically acceptable carrier.

37. A composition according to claim 36 wherein said Oligomer in a substantially neutral Oligomer.

38. A composition according to claim 37 which further comprises a flux enhancer.

10 39. A pharmaceutical composition comprising an amount of an Oligomer or Oligomers which interact with a gene coding for androgen receptor or 5-alpha-reductase or its transcription product or a target sequence immediately upstream from the transcription start site of said gene
15 effective to inhibit or alter expression of the androgen receptor or 5-alpha-reductase and a pharmaceutically acceptable carrier.

40. A composition according to claim 39 wherein said Oligomer or Oligomers are substantially neutral.

20 41. A composition according to claim 40 which further comprises a flux enhancer.

42. A composition according to claim 40 wherein said target sequence is selected from:

- 25 [1] (a) TTC CCC CAC TCT CTC TC,
[2] (b) CTC TCT CTC ACC TC, and
[3] (c) UCU CUC UUC CUU CCC.

43. A composition according to claim 40 wherein said Oligomer has the nucleoside sequence selected from:

- 30 [4] (a) GAG AGA GAG TGG GGG AA and
[5] (b) GAG GTG GAG AGA GAG.

SUBSTITUTE SHEET (RULE 26)




FIG. 1.

2/3





FIG. 2.

SUBSTITUTE SHEET (RULE 26)

3/3

FIG. 3.



INTERNATIONAL SEARCH REPORT

International application No.
T/US94/01748

A. CLASSIFICATION OF SUBJECT MATTER IPC(5) : A01N 43/04; A61K 31/70 US CL : 514/44 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/44 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APA, Chem. Abs.				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	Journal Society of Cosmetic Chemistry, Volume 24, issued 1973, K.D. Bingham et al, "Male Pattern Baldness and the Metabolism of Androgens by Human Scalp Skin", pages 523-536, see especially page 528 to page 530, line 8, page 531, figure 1 and page 532, lines 7-10.	1-43		
Y	Science, Volume 245, issued 18 August 1989, L. J. Maher et al, "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation", pages 725-730, especially page 729, col. 2, parag. 1 to page 730, line 12 and the abstract.	1-43		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: *A* document defining the general state of the art which is not considered to be part of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td> T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be part of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be part of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family			
Date of the actual completion of the international search 25 MAY 1994		Date of mailing of the international search report JUN 09 1994		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Stacy Shrank</i> Deborah Crouch, Ph.D. Telephone No. 703) 308-0196		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/01748

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Clinical Investigation, Volume 88, issued October 1991, R.M. Burch et al, "Oligonucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", pages 1190-1196, especially 1194, col. 1, parag. 2, lines 1-3.	1-43